Statin Use for Older Adults in Primary Care - October 2026 Journal Club
Interested in the current evidence on starting, continuing and stopping statins for primary prevention in older adults? This journal club explores two recently published trials on the use of statins in this age group, and their implications for general practice.
Date: Monday 12 October 2026
Time: 6–7pm AEST
Where: Online via Zoom
Statins are among the most commonly prescribed medicines in older adults, yet the evidence for starting them for primary prevention in this age group has been limited. Two recently published trials now speak directly to that decision, and to whether statins can be safely stopped in people already taking them.
This journal club will work through both trials and what they mean for everyday practice.
Discussion articles
Zoungas S, Wolfe R, Moran C, et al. Atorvastatin, cardiovascular events, and disability-free survival in older adults. The New England Journal of Medicine. 2026. doi:10.1056/NEJMoa2607314
Galli G, Rousset M, Coueron R, et al. Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial. The Lancet Healthy Longevity. 2026;7(7):100884. doi:10.1016/j.lanhl.2026.100884
The journal club included
A welcome and introductory case study from Professor Nick Zwar, local GP and Executive Dean, Faculty of Health Sciences and Medicine, Bond University.
A critical appraisal of both trials by Associate Professor Loai Albarqouni.
Expert commentary from guest speakers Professor Mark Nelson (Tasmanian School of Medicine, University of Tasmania), an author of the NEJM trial, and Professor Paul Glasziou (Emeritus Professor, Bond University), reflecting on the implications for primary care.
Open discussion and audience questions.
Slides and Video Recording Avaliable Below: